<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

What’s Next for Nuvectra? An Interview with CEO Scott Drees

Posted by Anne Staylor on 3/13/18 11:01 AM

Scott Drees, CEO of Nuvectra Corporation, discusses the Company’s challenges and opportunities in 2017, strategies for driving growth and market penetration in neuromodulation, and the Company’s key priorities for 2018 in an interview with SmartTRAK at the North American Neuromodulation Society Annual Meeting held Jan. 11-14, 2018 in Las Vegas, NV.

A transcript of SmartTRAK’s interview with Scott Drees is below, or click the following video to view the interview recorded live at NANS 2018. (17:41 minutes.)

Read More

Topics: Neuromodulation

SmartTRAK Attending ISC 2018 in Los Angeles CA

Posted by Anne Staylor on 1/22/18 9:00 AM

SmartTRAK is excited to be attending #ISC 2018 - International Stroke Conference, January 24-26 at the Los Angeles Convention Center.

The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease.

Read More

Topics: Neuromodulation, SmartTRAK Conferences

Vagal Nerve Stimulation With Rehab Improves Long-Term Stroke Recovery

Posted by Anne Staylor on 9/26/17 11:47 AM

SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.

One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.

At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...

Read More

Topics: Neuromodulation

SmartTRAK's Neuro Analyst, Anne Staylor, to Attend INS 2017

Posted by Rebecca Gonzalez on 5/25/17 3:18 PM

 SmartTRAK will be at the International Neuromodulation Society 13th World Congress “Neuromodulation: Technology Changing Lives” in Edinburgh, Scotland May 27- June 1. Meet with Anne Staylor, Senior SmartTRAK Analyst and Managing Editor!

Learn more care

Read More

Topics: Neuromodulation, Neurotherapies

Nuvectra: Positioned For Growth In Neuromodulation

Posted by Anne Staylor on 5/4/17 2:00 PM

It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.

Read More

Topics: Neuromodulation, Neurotherapies

Finding the Sweet Spot: Medtronic’s Growth Strategies for Spinal Cord Stimulation

Posted by Anne Staylor on 2/25/17 12:00 PM

In an interview with BioMedGPS, Medtronic’s Marshall Stanton, MD discussed the Company’s strategies for gaining back market share in spinal cord stimulation and ongoing efforts to find the sweet spot in treating chronic intractable pain.

Read More

Topics: Neuromodulation

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts